Table 1.

Children’s Hospital of Soochow University pediatric AML chemotherapy regimens

	Drug	Dose	Schedule	Days
Induction
LDC	Cytarabine	10 mg/m2	Every 12 h, subcutaneous	1-10
	Omacetaxine mepesuccinate* or mitoxantrone	1 mg/m2	Once per day, IV	1-7
		5 mg/m2	Once per day, IV	1, 3, 5
	G-CSF	5 µg/kg	Once per day, subcutaneous	1-10
SDC	Cytarabine	100 mg/m2	Every 12 h, IV	1-10
	Etoposide	100 mg/m2	Once per day, IV	1-5
	Omacetaxine mepesuccinate* or daunorubicin	3 mg/m2	Once per day, IV	1-7
		50 mg/m2	Once per day, IV	2, 4, 6
Postremission consolidation
I	Cytarabine	2 g/m2	Every 12 h, IV	1-3
	Mitoxantrone	10 mg/m2	Once per day, IV	3-5
II	Cytarabine	3 g/m2	Every 12 h, IV	1-3
	Etoposide	150 mg/m2	Once per day, IV	1-3
III	Cytarabine	3 g/m2	Every 12 h, IV	1, 2, 8, 9
	L-asparaginase	6000 U/m2	Once per day, intramuscular	3, 10
IV	Cytarabine	2 g/m2	Once per day, IV	1-5
	Fludarabine	30 mg/m2	Once per day, IV	1-5
	G-CSF	300 µg/m2	Once per day, subcutaneous	0-5

^*Mitoxantrone (n = 59) and daunorubicin (n = 81) were substituted for omacetaxine mepesuccinate in the LDC group (n = 24) and in the SDC group (n = 19).